Terms: = Prostate cancer AND KLK2, P20151, 3817, ENSG00000167751, MGC12201, hK2, KLK2A2 AND Diagnosis
63 results:
1. Construction of lncRNA/Pseudogene-miRNA Network Based on In Silico Approaches for Glycolysis Pathway to Identify prostate Adenocarcinoma-Related Potential Biomarkers.
Khorsand M; Mostafavi-Pour Z; Tahmasebi A; Omidvar Kordshouli S; Mousavi P
Appl Biochem Biotechnol; 2024 Apr; 196(4):2332-2355. PubMed ID: 37542606
[TBL] [Abstract] [Full Text] [Related]
2. Multi-marker risk-based screening for prostate cancer.
Wald NJ; Bestwick JP; Morris JK
J Med Screen; 2022 Jun; 29(2):123-133. PubMed ID: 35255236
[TBL] [Abstract] [Full Text] [Related]
3. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant prostate cancer.
Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
[TBL] [Abstract] [Full Text] [Related]
4. Serum Exosomal Gamma-Glutamyltransferase Activity Increased in Patients with Renal Cell Carcinoma with Advanced Clinicopathological Features.
Horie K; Kawakami K; Fujita Y; Matsuda Y; Arai T; Suzui N; Miyazaki T; Koie T; Mizutani K; Ito M
Oncology; 2020; 98(10):734-742. PubMed ID: 32726790
[TBL] [Abstract] [Full Text] [Related]
5. Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.
Ruiz-Plazas X; Rodríguez-Gallego E; Alves M; Altuna-Coy A; Lozano-Bartolomé J; Portero-Otin M; García-Fontgivell JF; Martínez-González S; Segarra J; Chacón MR
J Transl Med; 2019 Sep; 17(1):307. PubMed ID: 31500625
[TBL] [Abstract] [Full Text] [Related]
6. Gold interdigitated triple-microelectrodes for label-free prognosticative aptasensing of prostate cancer biomarker in serum.
Ibau C; Md Arshad MK; Gopinath SCB; Nuzaihan M N M; M Fathil MF; Estrela P
Biosens Bioelectron; 2019 Jul; 136():118-127. PubMed ID: 31054519
[TBL] [Abstract] [Full Text] [Related]
7. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
8. Diagnostic performance of PCA3 and hk2 in combination with serum PSA for prostate cancer.
Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L
Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974
[TBL] [Abstract] [Full Text] [Related]
9. Identification and characterization of novel fusion genes in prostate cancer by targeted RNA capture and next-generation sequencing.
Yang J; Chen Y; Lu J; Wang X; Wang L; Liang J; Sun ZS
Acta Biochim Biophys Sin (Shanghai); 2018 Nov; 50(11):1166-1172. PubMed ID: 30307468
[TBL] [Abstract] [Full Text] [Related]
10. "Mix-to-Go" Silver Colloidal Strategy for prostate cancer Molecular Profiling and Risk Prediction.
Wang J; Koo KM; Wang Y; Trau M
Anal Chem; 2018 Nov; 90(21):12698-12705. PubMed ID: 30260630
[TBL] [Abstract] [Full Text] [Related]
11. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
[TBL] [Abstract] [Full Text] [Related]
12. Genetic factors influencing prostate cancer risk in Norwegian men.
Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
[TBL] [Abstract] [Full Text] [Related]
13. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Thorek DL; Watson PA; Lee SG; Ku AT; Bournazos S; Braun K; Kim K; Sjöström K; Doran MG; Lamminmäki U; Santos E; Veach D; Turkekul M; Casey E; Lewis JS; Abou DS; van Voss MR; Scardino PT; Strand SE; Alpaugh ML; Scher HI; Lilja H; Larson SM; Ulmert D
Sci Transl Med; 2016 Nov; 8(367):367ra167. PubMed ID: 27903863
[TBL] [Abstract] [Full Text] [Related]
14. A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hk2) Immunoassay Platform toward Accurate diagnosis of prostate cancer.
Lee SW; Hosokawa K; Kim S; Jeong OC; Lilja H; Laurell T; Maeda M
Sensors (Basel); 2015 May; 15(5):11972-87. PubMed ID: 26007739
[TBL] [Abstract] [Full Text] [Related]
15. [Serum p2PSA derivative indexes in prostate cancer: an update].
Liu Y; Xu Y
Zhonghua Nan Ke Xue; 2015 Jan; 21(1):74-7. PubMed ID: 25707145
[TBL] [Abstract] [Full Text] [Related]
16. miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen.
Larne O; Östling P; Haflidadóttir BS; Hagman Z; Aakula A; Kohonen P; Kallioniemi O; Edsjö A; Bjartell A; Lilja H; Lundwall Å; Ceder Y
Eur Urol; 2015 Oct; 68(4):581-8. PubMed ID: 25556023
[TBL] [Abstract] [Full Text] [Related]
17. Kallikreins as biomarkers for prostate cancer.
Hong SK
Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
[TBL] [Abstract] [Full Text] [Related]
18. Kallikrein-related peptidases in cancers of gastrointestinal tract: an inside view of their role and clinical significance.
Linardoutsos D; Gazouli M; Machairas A; Bramis I; Zografos GC
J BUON; 2014; 19(1):53-9. PubMed ID: 24659643
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of fusion gene expression in prostate tumors by using single-end reads.
Xie DD; Li JY; Wang Y; Chen L; Yu DX
Genet Mol Res; 2013 Aug; 12(3):2886-94. PubMed ID: 24065644
[TBL] [Abstract] [Full Text] [Related]
20. Tumor markers in prostate cancer I: blood-based markers.
Shariat SF; Semjonow A; Lilja H; Savage C; Vickers AJ; Bjartell A
Acta Oncol; 2011 Jun; 50 Suppl 1(Suppl 1):61-75. PubMed ID: 21604943
[TBL] [Abstract] [Full Text] [Related]
[Next]
